跳至主要内容
临床试验/jRCT2031250576
jRCT2031250576招募中不适用

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

未提供0 个研究点目标入组 550 人开始时间: 待定
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
550

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • •Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • •Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
  • •Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
  • •Have at least one measurable lesion as the targeted lesion based on RECIST V1.
  • •Eastern Cooperative Oncology Group performance status of 0 or
  • •Adequate organ function

排除标准

  • •known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression
  • •Leptomeningeal disease
  • •Clinically significant risk of hemorrhage or fistula
  • •history of another malignancy within 3 years
  • •active autoimmune diseases requiring systemic treatment within the past 2 years

研究者

发起方
未提供

相似试验